BRIEF published on 07/24/2024 at 12:35, 3 months 27 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 3 months 27 days ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 7 months 1 day ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
PRESS RELEASE published on 04/19/2024 at 18:10, 7 months 1 day ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 7 months 24 days ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
PRESS RELEASE published on 03/27/2024 at 13:00, 7 months 24 days ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 11/21/2024 at 10:03, 28 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 31 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 31 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 56 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 6 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 26 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 29 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 31 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 31 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 30 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 33 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 11 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 46 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 46 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
